The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Overall survival of brain-only oligometastatic patients with cancer
Ariane Steindl, PhD, Medical University of Vienna, Vienna, Austria, presents findings from a trial investigating the clinical course of patients with brain-only oligometastatic disease. Patients with brain-only oligometastatic disease present with a more favorable survival prognosis than patients with additional extracranial involvement. Multidisciplinary treatment planning should be encouraged in patients with brain-only oligometastatic disease to address the high proportion of patients surviving more than 24 months. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
